于2026年9月8日,Cowin China Growth Fund II, L.P.以每股均价3.6117港元卖出银诺医药-B股份337.00万股,涉资约1217.14万港元。
Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓1778.64万股,占比4.23%;减持后持股量为1441.64万股,好仓比例降至3.43%。
于2026年9月8日,Cowin China Growth Fund II, L.P.以每股均价3.6117港元卖出银诺医药-B股份337.00万股,涉资约1217.14万港元。
Cowin China Growth Fund II, L.P.此次减持前持有银诺医药-B好仓1778.64万股,占比4.23%;减持后持股量为1441.64万股,好仓比例降至3.43%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.